Pegfilgrastim vs Filgrastim: What Are the Differences?

Pegfilgrastim and filgrastim are both forms of granulocyte colony-stimulating factor (G-CSF), a protein that tells the bone marrow to make more neutrophils, the white blood cells that fight bacterial infections. The core molecule is the same, but pegfilgrastim has a large polyethylene glycol (PEG) chain attached to it, which changes how the body processes the drug and, in turn, how often you need to take it. That single structural modification creates a cascade of practical differences in dosing, clearance, cost, and convenience that matter to anyone going through chemotherapy.

The Same Molecule With a Different Wrapper

Filgrastim is a lab-made version of the G-CSF your body naturally produces. It is not an exact copy: it has an extra methionine amino acid at one end and lacks the sugar molecules found on the natural protein. But it has the same biological activity, driving the growth, maturation, and activation of neutrophil precursors in the bone marrow.¹ Both drugs exist to solve the same problem: chemotherapy kills fast-dividing cells indiscriminately, which hammers the bone marrow and causes dangerously low neutrophil counts, a condition called neutropenia. Severe neutropenia leaves you vulnerable to infections that a healthy immune system would handle easily.

Pegfilgrastim was created by attaching a 20-kilodalton PEG chain to filgrastim’s N-terminal end through a precise chemical process called site-directed reductive alkylation.² PEG itself is biologically inert. Think of it as a bulky, water-loving coat wrapped around the active protein. That coat does not change what filgrastim does once it reaches its target, but it dramatically changes how long the drug stays in the bloodstream.

Why the PEG Chain Changes Everything About Clearance

Filgrastim is a small protein, and the kidneys filter it out of the blood fairly quickly. It has a plasma half-life of roughly three to four hours, meaning half the injected dose is gone in that time.³ The body also clears filgrastim through a second route: neutrophils themselves grab onto G-CSF through receptors on their surface, pull it inside, and break it down. So filgrastim disappears through two exits at once, kidneys and neutrophils.

Pegfilgrastim’s PEG coat makes the molecule too large to pass through the kidney’s filtration system. Studies in animals whose kidneys were surgically removed, and in human patients with kidney impairment, confirmed that renal clearance becomes negligible once the PEG chain is attached.⁴ That leaves neutrophil-mediated clearance as the dominant way the body eliminates pegfilgrastim. This creates a self-regulating loop: when your neutrophil count is at its lowest (the nadir), there are few neutrophils around to clear the drug, so pegfilgrastim levels stay high and keep stimulating the marrow. As neutrophils recover, they mop up the remaining drug and levels drop.⁵ In pediatric sarcoma patients, pegfilgrastim’s terminal half-life was measured at about 49 hours, compared to much faster clearance for filgrastim.⁶

Dosing Schedules and What They Mean for Your Daily Life

The practical upshot of everything above is that filgrastim requires daily injections, typically starting a day or two after chemotherapy and continuing for roughly 10 to 14 days or until neutrophil counts bounce back. In clinical trials, the standard dose has been 5 micrograms per kilogram of body weight per day.⁷ Pegfilgrastim, by contrast, is given as a single fixed-dose injection of 6 mg once per chemotherapy cycle. One shot instead of potentially 11 or more. For people already exhausted from treatment, the difference in clinic visits and injection burden is not trivial.

An expert consensus panel agreed that pegfilgrastim and 11 days of filgrastim have similar effectiveness and safety, but flagged that pegfilgrastim is preferred over shorter courses of filgrastim because fewer daily injections often means missed doses in the real world.⁸ The same panel noted that pegfilgrastim is not appropriate for weekly chemotherapy regimens, because the drug’s long duration could overlap with the next dose of chemo. In palliative chemotherapy settings, where quality of life takes priority, the convenience factor often tips the balance toward pegfilgrastim.

The On-Body Injector

Guidelines recommend giving pegfilgrastim about 24 hours after chemotherapy, which traditionally meant coming back to the clinic the next day. To get around this, an on-body injector (OBI) was developed: a small, battery-powered device stuck to the skin on the day of chemo that automatically delivers the dose roughly 27 hours later over about 45 minutes.⁹ The reported delivery success rate is above 99%.¹⁰ Early concerns centered on device failures and patient unfamiliarity, but a retrospective analysis of real-world outcomes found the device performed well in clinical practice.¹¹ The OBI is unique to pegfilgrastim and has no filgrastim equivalent, making it one more practical differentiator between the two drugs.

How the Two Drugs Compare on Preventing Febrile Neutropenia

A meta-analysis pooling five randomized controlled trials with a total of 617 patients compared a single dose of pegfilgrastim per cycle against daily filgrastim injections for preventing febrile neutropenia, the dangerous combination of fever and very low neutrophil counts.¹² The headline finding across the available evidence is that the two are similarly effective when filgrastim is given for the full recommended duration.¹³ The trouble is that outside of clinical trials, patients on filgrastim frequently receive fewer days of injections than ideal, which can erode that equivalence. Pegfilgrastim sidesteps this adherence problem entirely because there is only one injection to give.

Side Effects and Serious Risks

The most common side effect of both drugs is bone pain, typically felt in the back, pelvis, or limbs. It makes sense physiologically: G-CSF is aggressively pushing the bone marrow to churn out neutrophils, and that expansion can hurt. A head-to-head comparison in breast cancer patients found no statistically significant differences in the rate, severity, or duration of bone pain between pegfilgrastim and filgrastim.¹⁴ Other side effects shared by both include injection-site reactions, headache, and fatigue.

Splenic rupture is a rare but serious risk associated with any G-CSF product. A pharmacovigilance analysis of the FDA’s adverse event reporting database found significantly elevated reporting odds ratios for splenic rupture with both pegfilgrastim and filgrastim, though the disproportionality signal was higher for filgrastim than for pegfilgrastim.¹⁵ Reporting databases are not the same as incidence studies, so the actual risk is hard to pin down, but both drug labels carry warnings about it. Patients are generally advised to report sudden left upper abdominal or shoulder pain promptly.

Cost and the Biosimilar Landscape

Filgrastim biosimilars have been available for over a decade and dramatically lowered prices. By 2019, seven pegfilgrastim biosimilars had been licensed as well, creating competitive pricing pressure on the long-acting side of the market.¹³ A three-way randomized equivalence trial comparing a proposed pegfilgrastim biosimilar against the US-licensed and EU-approved reference products showed comparable results across endpoints including duration of severe neutropenia, depth of neutrophil nadir, time to recovery, and febrile neutropenia rates.¹⁶

Even with biosimilars in play, pegfilgrastim generally carries a higher per-cycle sticker price than a course of filgrastim, though the gap has narrowed. A systematic review of cost-effectiveness studies in lymphoma patients found a wide range of results depending on the country and healthcare setting. Several of those studies concluded that pegfilgrastim was cost-effective or even dominant (meaning it saved money overall) when you factor in the reduced need for clinic visits and hospitalization from febrile neutropenia episodes.¹⁷ The calculus shifts depending on local drug pricing, how many days of filgrastim a patient actually receives, and whether the healthcare system bears the cost of extra clinic visits.

Pegfilgrastim and Filgrastim in Children and Young Adults

Most of the landmark trials were conducted in adults with breast cancer, so the pediatric data are thinner. A randomized trial in young adults and children with sarcomas found that the number of days of severe neutropenia was not significantly different between the two drugs. Febrile neutropenia episodes requiring hospitalization occurred in about 29% of chemotherapy cycles with pegfilgrastim versus 47% with filgrastim, a numerical advantage but in a small trial of 34 patients.⁶ Both drugs were well tolerated in this age group, with similar adverse event profiles. The practical advantage of a single injection per cycle is arguably even more appealing in pediatric patients, where daily injections can be distressing for both the child and the family.

Stem Cell Mobilization

Outside of preventing neutropenia during chemotherapy, both drugs are used to push stem cells out of the bone marrow and into the bloodstream so they can be collected for transplant. A systematic review and meta-analysis of this use found that pegfilgrastim and filgrastim produced similar yields of the target stem cells (CD34+ cells). Pegfilgrastim had a small advantage in that patients started collection earlier and needed fewer collection sessions.¹⁸ Recovery times for white blood cells and platelets after transplant were similar between the two.

A separate randomized trial found that the timing of pegfilgrastim relative to the mobilizing chemotherapy matters. Giving pegfilgrastim on day 7 after cyclophosphamide produced a successful mobilization rate of about 71%, comparable to daily filgrastim at about 64%, but giving pegfilgrastim on day 3 dropped the success rate to roughly 48%.¹⁹ So while pegfilgrastim can work as a convenient single-dose mobilization agent, getting the timing right is critical, and filgrastim’s flexibility with daily dosing can be an advantage when the clinical picture is unpredictable.

Filgrastim Beyond Cancer

Filgrastim has a broader set of approved indications than pegfilgrastim. It is used in patients with chronic severe neutropenia unrelated to cancer, in people undergoing bone marrow transplant, and in healthy donors providing stem cells for someone else’s transplant. It is also one of a handful of drugs approved by the US FDA for treating hematopoietic acute radiation syndrome, the bone marrow failure that follows significant radiation exposure.²⁰ Pegfilgrastim’s indication is narrower, focused primarily on chemotherapy-induced neutropenia, though it has been studied in some of these other settings as well. The daily dosing flexibility of filgrastim gives clinicians more control in situations where the clinical course is uncertain or where treatment duration needs to be dialed up or down on short notice.

Immunogenicity

Any therapeutic protein can trigger the immune system to produce antibodies against it. With pegfilgrastim, most of the antibodies that do develop are directed against the PEG portion of the molecule rather than against the filgrastim protein itself. A randomized trial comparing a pegfilgrastim biosimilar to the reference product in healthy volunteers found low rates of treatment-induced antibodies in both groups, with no neutralizing antibodies against filgrastim detected.²¹ A pooled analysis of lipegfilgrastim (a glycopegylated variant) versus pegfilgrastim across two clinical trials found treatment-emergent antibody rates of about 1% in both groups, and again no neutralizing activity.²² In practice, immunogenicity has not been a clinically significant problem with either drug, though it is monitored during biosimilar development programs.

What G-CSF Does to Imaging Scans

One underappreciated wrinkle with any G-CSF, pegfilgrastim included, is its effect on PET/CT scans. When the bone marrow is revved up making neutrophils, it takes up more of the radioactive glucose tracer used in PET imaging. A study in lymphoma patients found that bone marrow tracer uptake increased by an average of about 32% on interim scans performed during chemotherapy with G-CSF support, with splenic uptake also rising.²³ These changes can mimic disease progression or mask genuine findings, and the effect was more pronounced the sooner the scan was done after the end of chemotherapy. The timing between the G-CSF injection itself and the scan mattered less than the interval after the last chemo dose. Radiologists and oncologists generally try to schedule PET scans with enough breathing room after a G-CSF course to minimize this artifact, but pegfilgrastim’s longer presence in the body can make scheduling trickier than with filgrastim, which clears within a day or two.